Federal award (DEFINITIVE CONTRACT, fiscal year 2023)
Recipient: IMMUNOTARGET THERAPEUTICS INC
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2022-02-07 to 2024-09-30
Current total value of award: $355000
Description: SMALL BUSINESS INNOVATION RESEARCH (SBIR) INNOVATIVE CONCEPT AWARD - DETECTION, DIAGNOSIS, TREATMENT, PREVENTION AND RESEARCH OF PEDIATRIC CANCERS AND/OR RARE CANCERS